Sugi Predict

Sugi Predict / Targets / RAC3

RAC3

Ras-related C3 botulinum toxin substrate 3 · P60763 · RAC3 on Sugi Atlas →

1,200 patent compounds predicted against RAC3, 789 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1461351 SCHEMBL1461351 1.00 1/20
Mbq-167 Mbq-167 (SCHEMBL19514489) 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL384979) 0.98 1/20
SCHEMBL1460422 SCHEMBL1460422 0.87 1/20
SCHEMBL19531601 SCHEMBL19531601 0.85 1/20
SCHEMBL1461760 SCHEMBL1461760 0.84 1/20
SCHEMBL1461794 SCHEMBL1461794 0.84 1/20
SCHEMBL1461829 SCHEMBL1461829 0.84 1/20
SCHEMBL4499457 SCHEMBL4499457 0.84 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1461295) 0.83 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1461390) 0.83 1/20
SCHEMBL19531596 SCHEMBL19531596 0.83 1/20
SCHEMBL19531598 SCHEMBL19531598 0.83 1/20
SCHEMBL20677953 SCHEMBL20677953 0.82 1/20
SCHEMBL19531619 SCHEMBL19531619 0.82 1/20
SCHEMBL19514500 SCHEMBL19514500 0.81 1/20
SCHEMBL19514602 SCHEMBL19514602 0.81 1/20
SCHEMBL1461466 SCHEMBL1461466 0.81 1/20
SCHEMBL4161227 SCHEMBL4161227 0.81 1/20
SCHEMBL19531592 SCHEMBL19531592 0.81 1/20

Clinical trials — most relevant to RAC3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 PHASE2COMPLETED
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) PHASE2COMPLETED
Responders to Rhythmic Auditory Cueing in Parkinson Disease PHASE1COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Gait in Rare Diseases nanCOMPLETED
Identification of New Biomarkers of Insulin Resistance nanACTIVE_NOT_RECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms nanCOMPLETED
Biomarkers of CASH nanACTIVE_NOT_RECRUITING
Parkinson's Families Project nanRECRUITING
Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis nanCOMPLETED
Blood-based Biomarkers for the Prognosis of Sports Related Concussion nanCOMPLETED
Prevalence and Characterization of Pain in RASopathies nanUNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia nanUNKNOWN
Genetic Analysis of Familial Melanoma nanCOMPLETED
Family Myopia Study nanCOMPLETED
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
Congenital Hemolytic and Dyserythropoietic Anemias nanRECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others nanRECRUITING
Targeted Nutritional Supplement After Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial nanWITHDRAWN
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RAC3 binder may also engage these)

ProteinNameSimilarity
P60764 — 1.000 P60764 →
RAC1 Ras-related C3 botulinum toxin substrate 1 0.999 landscape →
P62999 — 0.999 P62999 →
Q9TU25 — 0.998 Q9TU25 →
P40792 — 0.998 P40792 →
P62998 — 0.997 P62998 →
RAC2 Ras-related C3 botulinum toxin substrate 2 0.997 landscape →
Q03206 — 0.997 Q03206 →
Q05144 — 0.996 Q05144 →
O88931 — 0.995 O88931 →
Q6RUV5 — 0.995 Q6RUV5 →
P63001 — 0.995 P63001 →
P48554 — 0.993 P48554 →
A0A286QZ36 — 0.991 A0A286QZ36 →
Q05062 — 0.985 Q05062 →
CDC42 Cell division control protein 42 homolog 0.985 landscape →
P60766 — 0.985 P60766 →
P60952 — 0.984 P60952 →
P24406 — 0.984 P24406 →
Q7T2E8 — 0.984 Q7T2E8 →
Q8CFN2 — 0.983 Q8CFN2 →
Q007T2 — 0.983 Q007T2 →
P61589 — 0.983 P61589 →
Q22038 — 0.982 Q22038 →
Q9C3Y4 — 0.981 Q9C3Y4 →
P48148 — 0.980 P48148 →
Q1RMJ6 — 0.980 Q1RMJ6 →
C4YDI6 — 0.980 C4YDI6 →
P61585 — 0.980 P61585 →
RHOA Transforming protein RhoA 0.980 landscape →